1,2-Difluoro-4-pentan-3-ylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,2-Difluoro-4-pentan-3-ylbenzene
• 英文别名: 1,2-difluoro-4-pentan-3-ylbenzene
• 化学式: C₁₁H₁₄F₂
• 分子量: 184.23
• InChiKey: KNPFXUDCBKITSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Spirocyclic compounds as tryptophan hydroxylase inhibitors
  申请人：Roivant Sciences GmbH

  公开号：US10350208B2

  公开（公告）日：2019-07-16

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及的螺环化合物是色氨酸羟化酶（TPH），特别是同工酶 1（TPH1）的抑制剂，可用于治疗与外周血清素相关的疾病或失调，例如包括胃肠道、心血管、肺、炎症、代谢和低骨量疾病，以及血清素综合征和癌症。
• Analogs for the treatment of disease
  申请人：Insilico Medicine IP Limited

  公开号：US11530197B2

  公开（公告）日：2022-12-20

  The disclosure provides TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.

  本公开提供了用于治疗疾病的 TNIK 和/或 MAP4K4 激酶抑制剂。在一个方面，本文公开了具有式(A)、(A*)、(I)、(IIA)或(IIB)结构的激酶抑制剂。本文进一步描述了包含这些化合物的药物组合物和使用这些化合物的方法。在一个方面，本文公开了通过施用本文所述激酶抑制剂治疗疾病或病症的方法。
• SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
  申请人：Karos Pharmaceuticals, Inc.

  公开号：US20170095476A1

  公开（公告）日：2017-04-06

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
• PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170246157A1

  公开（公告）日：2017-08-31

  The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
• US9750740B2
  申请人：——

  公开号：US9750740B2

  公开（公告）日：2017-09-05